RU2018138837A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018138837A3 RU2018138837A3 RU2018138837A RU2018138837A RU2018138837A3 RU 2018138837 A3 RU2018138837 A3 RU 2018138837A3 RU 2018138837 A RU2018138837 A RU 2018138837A RU 2018138837 A RU2018138837 A RU 2018138837A RU 2018138837 A3 RU2018138837 A3 RU 2018138837A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1606156.6 | 2016-04-08 | ||
| GB201606156 | 2016-04-08 | ||
| PCT/EP2017/058578 WO2017174823A1 (en) | 2016-04-08 | 2017-04-10 | T cell receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018138837A RU2018138837A (ru) | 2020-05-12 |
| RU2018138837A3 true RU2018138837A3 (ru) | 2020-07-30 |
Family
ID=58536983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018138837A RU2018138837A (ru) | 2016-04-08 | 2017-04-10 | Т-клеточные рецепторы |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190144521A1 (ru) |
| EP (2) | EP3925972A1 (ru) |
| JP (2) | JP7204484B2 (ru) |
| KR (1) | KR20190065189A (ru) |
| CN (2) | CN116239669A (ru) |
| AU (2) | AU2017248121B2 (ru) |
| BR (1) | BR112018070637A2 (ru) |
| CA (1) | CA3020555A1 (ru) |
| ES (1) | ES2788188T5 (ru) |
| IL (1) | IL262124A (ru) |
| MX (1) | MX2018012268A (ru) |
| RU (1) | RU2018138837A (ru) |
| SG (1) | SG11201808750PA (ru) |
| WO (1) | WO2017174823A1 (ru) |
| ZA (1) | ZA201806862B (ru) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| ES2896919T3 (es) | 2014-12-23 | 2022-02-28 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (CHC) y otros tipos de cáncer |
| MX2018012268A (es) * | 2016-04-08 | 2019-02-07 | Adaptimmune Ltd | Receptores de celulas t. |
| EP4389898A2 (en) * | 2016-04-08 | 2024-06-26 | Adaptimmune Ltd | T cell receptors |
| AU2017248122B2 (en) | 2016-04-08 | 2022-07-21 | Adaptimmune Limited | T cell receptors |
| WO2019069125A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
| EP3747456A4 (en) * | 2018-01-31 | 2021-12-01 | Tohoku University | PROCESS FOR REGULATING THE EXPRESSION OF THE SPECIFIC MHC OF AN ANTIGEN |
| CA3097399A1 (en) * | 2018-04-19 | 2019-10-24 | The Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
| CN110172091B (zh) * | 2019-04-28 | 2020-04-03 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| US20220324939A1 (en) * | 2019-06-18 | 2022-10-13 | Regeneron Pharmaceuticals, Inc. | Mage-a4 t cell receptors and methods of use thereof |
| CN114245807A (zh) | 2019-06-25 | 2022-03-25 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| US20210048442A1 (en) | 2019-08-13 | 2021-02-18 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:mhc binding polypeptides |
| CA3150818A1 (en) | 2019-08-13 | 2021-02-18 | King's College London | Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily |
| US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
| CN111647069B (zh) * | 2020-06-17 | 2022-06-21 | 深圳豪石生物科技有限公司 | 一种改进的tcr及其应用 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20240100162A1 (en) * | 2020-12-22 | 2024-03-28 | Amgen Inc. | Mage-b2-specific t-cell receptors |
| KR20230169944A (ko) | 2021-03-09 | 2023-12-18 | 씨디알-라이프 아게 | Mage-a4 펩티드-mhc 항원 결합 단백질 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CN118201941A (zh) | 2021-10-29 | 2024-06-14 | 吉利德科学公司 | Cd73化合物 |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN116836261A (zh) * | 2022-03-24 | 2023-10-03 | 香雪生命科学技术（广东）有限公司 | 一种识别mage-a4抗原的高亲和力tcr及其序列和应用 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN117106060A (zh) * | 2022-05-17 | 2023-11-24 | 香雪生命科学技术（广东）有限公司 | 一种识别mage的高亲和力t细胞受体及其应用 |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596536B1 (en) * | 1991-02-08 | 2003-07-22 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| US6710172B1 (en) | 1998-10-02 | 2004-03-23 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
| US6407063B1 (en) * | 1998-10-02 | 2002-06-18 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
| US6867283B2 (en) * | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US20050053918A1 (en) | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
| ATE290020T1 (de) | 2001-08-31 | 2005-03-15 | Avidex Ltd | Löslicher t zell rezeptor |
| GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| BRPI0924556A2 (pt) | 2009-06-09 | 2015-06-30 | Vaxon Biotech | "identificação, otimização e uso de epítopos hla-b*0702 compartilhados para imunoterapia" |
| PL2618835T3 (pl) | 2010-09-20 | 2017-12-29 | Biontech Cell & Gene Therapies Gmbh | Swoiste względem antygenu receptory komórek T i epitopy dla komórek T |
| SG11201400521PA (en) * | 2011-10-14 | 2014-08-28 | Teva Pharmaceuticals Australia Pty Ltd | ANTIBODIES TO CD1d |
| KR102301464B1 (ko) * | 2013-06-10 | 2021-09-14 | 다나-파버 캔서 인스티튜트 인크. | 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물 |
| JP6255360B2 (ja) * | 2015-03-04 | 2017-12-27 | ヴァクソン バイオテックＶａｘｏｎ Ｂｉｏｔｅｃｈ | 共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用 |
| MX2018012268A (es) | 2016-04-08 | 2019-02-07 | Adaptimmune Ltd | Receptores de celulas t. |
| SG11201808797XA (en) | 2016-04-08 | 2018-11-29 | Immunocore Ltd | T cell receptors |
| AU2017248122B2 (en) | 2016-04-08 | 2022-07-21 | Adaptimmune Limited | T cell receptors |
| EP4389898A2 (en) | 2016-04-08 | 2024-06-26 | Adaptimmune Ltd | T cell receptors |
-
2017
- 2017-04-10 MX MX2018012268A patent/MX2018012268A/es unknown
- 2017-04-10 CN CN202310214446.3A patent/CN116239669A/zh active Pending
- 2017-04-10 RU RU2018138837A patent/RU2018138837A/ru unknown
- 2017-04-10 EP EP20020115.0A patent/EP3925972A1/en active Pending
- 2017-04-10 EP EP17716871.3A patent/EP3440104B2/en active Active
- 2017-04-10 CA CA3020555A patent/CA3020555A1/en active Pending
- 2017-04-10 KR KR1020187032157A patent/KR20190065189A/ko not_active Application Discontinuation
- 2017-04-10 AU AU2017248121A patent/AU2017248121B2/en active Active
- 2017-04-10 CN CN201780031701.3A patent/CN109476724B/zh active Active
- 2017-04-10 JP JP2018552775A patent/JP7204484B2/ja active Active
- 2017-04-10 WO PCT/EP2017/058578 patent/WO2017174823A1/en active Application Filing
- 2017-04-10 SG SG11201808750PA patent/SG11201808750PA/en unknown
- 2017-04-10 ES ES17716871T patent/ES2788188T5/es active Active
- 2017-04-10 BR BR112018070637A patent/BR112018070637A2/pt not_active Application Discontinuation
-
2018
- 2018-10-04 IL IL262124A patent/IL262124A/en unknown
- 2018-10-08 US US16/154,270 patent/US20190144521A1/en not_active Abandoned
- 2018-10-15 ZA ZA2018/06862A patent/ZA201806862B/en unknown
-
2021
- 2021-10-14 US US17/501,200 patent/US11753456B2/en active Active
-
2022
- 2022-05-24 JP JP2022084419A patent/JP2022122913A/ja active Pending
- 2022-10-20 AU AU2022256182A patent/AU2022256182A1/en active Pending
-
2023
- 2023-08-01 US US18/363,672 patent/US20240010702A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022256182A1 (en) | 2022-11-24 |
| SG11201808750PA (en) | 2018-11-29 |
| CA3020555A1 (en) | 2017-10-12 |
| US20240010702A1 (en) | 2024-01-11 |
| ZA201806862B (en) | 2021-04-28 |
| EP3440104B1 (en) | 2020-03-11 |
| US20220025013A1 (en) | 2022-01-27 |
| BR112018070637A2 (pt) | 2019-02-05 |
| US20190144521A1 (en) | 2019-05-16 |
| RU2018138837A (ru) | 2020-05-12 |
| CN109476724B (zh) | 2023-04-04 |
| JP2022122913A (ja) | 2022-08-23 |
| ES2788188T5 (es) | 2023-10-24 |
| CN116239669A (zh) | 2023-06-09 |
| AU2017248121B2 (en) | 2022-07-21 |
| KR20190065189A (ko) | 2019-06-11 |
| JP2019516356A (ja) | 2019-06-20 |
| ES2788188T3 (es) | 2020-10-20 |
| EP3925972A1 (en) | 2021-12-22 |
| WO2017174823A4 (en) | 2017-12-07 |
| IL262124A (en) | 2018-11-29 |
| WO2017174823A1 (en) | 2017-10-12 |
| US11753456B2 (en) | 2023-09-12 |
| AU2017248121A1 (en) | 2018-11-22 |
| CN109476724A (zh) | 2019-03-15 |
| EP3440104A1 (en) | 2019-02-13 |
| EP3440104B2 (en) | 2023-06-14 |
| JP7204484B2 (ja) | 2023-01-16 |
| MX2018012268A (es) | 2019-02-07 |